Authors:
Solorzano, CC
Baker, CH
Tsan, R
Traxler, P
Cohen, P
Buchdunger, E
Killion, JJ
Fidler, IJ
Citation: Cc. Solorzano et al., Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma, CLIN CANC R, 7(8), 2001, pp. 2563-2572
Authors:
Garcia-Echeverria, C
Traxler, P
Evans, DB
Citation: C. Garcia-echeverria et al., ATP site-directed competitive and irreversible inhibitors of protein kinases, MED RES REV, 20(1), 2000, pp. 28-57
Authors:
Bold, G
Altmann, KH
Frei, J
Lang, M
Manley, PW
Traxler, P
Wietfeld, B
Bruggen, J
Buchdunger, E
Cozens, R
Ferrari, S
Furet, P
Hofmann, F
Martiny-Baron, G
Mestan, J
Rosel, J
Sills, M
Stover, D
Acemoglu, F
Boss, E
Emmenegger, R
Lasser, L
Masso, E
Roth, R
Schlachter, C
Vetterli, W
Wyss, D
Wood, JM
Citation: G. Bold et al., New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis (vol 43, pg 2316, 2000), J MED CHEM, 43(16), 2000, pp. 3200-3200
Authors:
Bold, G
Altmann, KH
Frei, J
Lang, M
Manley, PW
Traxler, P
Wietfeld, B
Bruggen, J
Buchdunger, E
Cozens, R
Ferrari, S
Furet, P
Hofmann, F
Martiny-Baron, G
Mestan, J
Rosel, J
Sills, M
Stover, D
Acemoglu, F
Boss, E
Emmenegger, R
Lasser, L
Masso, E
Roth, R
Schlachter, C
Vetterli, W
Wyss, D
Wood, JM
Citation: G. Bold et al., New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis, J MED CHEM, 43(12), 2000, pp. 2310-2323
Authors:
Bruns, CJ
Solorzano, CC
Harbison, MT
Ozawa, S
Tsan, R
Fan, D
Abbruzzese, J
Traxler, P
Buchdunger, E
Radinsky, R
Fidler, IJ
Citation: Cj. Bruns et al., Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma, CANCER RES, 60(11), 2000, pp. 2926-2935
Authors:
Weidner, S
Goeke, K
Trinks, U
Traxler, P
Ucci-Stoll, K
Ghisalba, O
Citation: S. Weidner et al., Preparation of 4-(4 '-hydroxyanilino)-5-anilinophthalimide and 4,5-bis-(4 '-hydroxyanilino)-phthalimide by microbial hydroxylation, BIOS BIOT B, 63(8), 1999, pp. 1497-1500
Citation: P. Traxler et P. Furet, Strategies toward the design of novel and selective protein tyrosine kinase inhibitors, PHARM THERA, 82(2-3), 1999, pp. 195-206
Authors:
Traxler, P
Green, J
Mett, H
Sequin, U
Furet, P
Citation: P. Traxler et al., Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: Isoflavones and 3-phenyl-4(1H)-quinolones, J MED CHEM, 42(6), 1999, pp. 1018-1026
Authors:
Lydon, N
Mett, H
Mueller, M
Becker, M
Cozens, RM
Daniels, D
Traxler, P
Buchdunger, E
Stover, D
Citation: N. Lydon et al., A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitroand in vivo. (vol 76, pg 154, 1998), INT J CANC, 81(4), 1999, pp. 669-669